 Thiotepa
"Thiotepa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
| Descriptor ID |
D013852
|
| MeSH Number(s) |
D02.705.539.950 D02.886.309.950 D03.383.097.217.935.960
|
| Concept/Terms |
Thiotepa- Thiotepa
- Thio-Tepa
- Thio Tepa
- Tris(1-aziridinyl)phosphine Sulfide
- Thiophosphamide
- Triethylenethiophosphoramide
|
Below are MeSH descriptors whose meaning is more general than "Thiotepa".
Below are MeSH descriptors whose meaning is more specific than "Thiotepa".
This graph shows the total number of publications written about "Thiotepa" by people in this website by year, and whether "Thiotepa" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1987 | 0 | 1 | 1 | | 1988 | 1 | 0 | 1 | | 1989 | 1 | 1 | 2 | | 1990 | 1 | 1 | 2 | | 1993 | 0 | 1 | 1 | | 1995 | 0 | 1 | 1 | | 1996 | 0 | 1 | 1 | | 1997 | 1 | 0 | 1 | | 1998 | 2 | 0 | 2 | | 1999 | 1 | 0 | 1 | | 2000 | 0 | 2 | 2 | | 2001 | 0 | 2 | 2 | | 2003 | 1 | 1 | 2 | | 2004 | 0 | 2 | 2 | | 2006 | 0 | 1 | 1 | | 2008 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Thiotepa" by people in Profiles.
-
Mohile NA, Forsyth P, Stewart D, Raizer JJ, Paleologos N, Kewalramani T, Louis DN, Cairncross JG, Abrey LE. A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis. J Neurooncol. 2008 Sep; 89(2):187-93.
-
Abrey LE, Childs BH, Paleologos N, Kaminer L, Rosenfeld S, Salzman D, Finlay JL, Gardner S, Peterson K, Hu W, Swinnen L, Bayer R, Forsyth P, Stewart D, Smith AM, Macdonald DR, Weaver S, Ramsay DA, Nimer SD, DeAngelis LM, Cairncross JG. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. Neuro Oncol. 2006 Apr; 8(2):183-8.
-
RamÃrez J, Innocenti F, Schuetz EG, Flockhart DA, Relling MV, Santucci R, Ratain MJ. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos. 2004 Sep; 32(9):930-6.
-
Campbell AD, Cohn SL, Reynolds M, Seshadri R, Morgan E, Geissler G, Rademaker A, Marymount M, Kalapurakal J, Haut PR, Duerst R, Kletzel M. Treatment of relapsed Wilms' tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children's Memorial Hospital. J Clin Oncol. 2004 Jul 15; 22(14):2885-90.
-
Abrey LE, Childs BH, Paleologos N, Kaminer L, Rosenfeld S, Salzman D, Finlay JL, Gardner S, Peterson K, Hu W, Swinnen L, Bayer R, Forsyth P, Stewart D, Smith AM, Macdonald DR, Weaver S, Ramsey DA, Nimer SD, DeAngelis LM, Cairncross JG. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma. J Neurooncol. 2003 Nov; 65(2):127-34.
-
van Besien K, Devine S, Wickrema A, Jessop E, Amin K, Yassine M, Maynard V, Stock W, Peace D, Ravandi F, Chen YH, Cheung T, Vijayakumar S, Hoffman R, Sosman J. Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies. Bone Marrow Transplant. 2003 Jul; 32(1):9-13.
-
Bibawi S, Abi-Said D, Fayad L, Anderlini P, Ueno NT, Mehra R, Khouri I, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Andreeff M, Andersson BS, Estey EH, Champlin R, Przepiorka D. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Am J Hematol. 2001 Aug; 67(4):227-33.
-
Sosman JA, Stiff P, Moss SM, Sorokin P, Martone B, Bayer R, van Besien K, Devine S, Stock W, Peace D, Chen Y, Long C, Gustin D, Viana M, Hoffman R. Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion. J Clin Oncol. 2001 Feb 01; 19(3):634-44.
-
Cairncross G, Swinnen L, Bayer R, Rosenfeld S, Salzman D, Paleologos N, Kaminer L, Forsyth P, Stewart D, Peterson K, Hu W, Macdonald D, Ramsay D, Smith A. Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. Neuro Oncol. 2000 04; 2(2):114-9.
-
Laport GG, Valone FH, Zimmerman TM, Grinblatt DL, Van Vlasselaer P, Still BJ, Williams SF. Transplantation with low-density autologous PBSC prepared with BDS60 for women with Stage II, III and IV breast cancer. Cytotherapy. 2000; 2(3):179-85.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|